ClinicalTrials.Veeva

Menu

Efficacy of Hyoscine-n-butylbromide in Catheter-related Bladder Discomfort After Elective Cesarean Section.

Cairo University (CU) logo

Cairo University (CU)

Status

Completed

Conditions

Catheter Related Bladder Discomfort

Treatments

Drug: hyoscine-n-butylbromide
Drug: control group

Study type

Interventional

Funder types

Other

Identifiers

NCT03513250
bladder discomfort

Details and patient eligibility

About

a prospective, randomized, placebo-controlled study will be conducted to investigate whether hyoscine-n-butylbromide has preventive effects on early postoperative CRBD in patients with urinary catheters who will undergo elective cesarean sections.

Full description

The insertion of a urinary catheter in a patient undergoing a surgical procedure as cesarean section may lead to catheter-related bladder discomfort with varying degrees of severity during the postoperative period. Catheter-related bladder discomfort (CRBD) symptoms associated with an indwelling urinary catheter are similar to overactive bladder symptoms such as discomfort in the suprapubic region, urinary urgency, frequency, burning sensation with or without urge incontinence. Hyoscine N-butyl bromide also known as scopolamine is a drug with anticholinergic effects which exerts its effects by inhibiting the acetylcholine effects in parasympathetic receptors of smooth muscle cells, secretory glands, and central nervous system. Hyoscine-n-butylbromide was reported to be effective for treatment of CRBD.

More preventive than therapeutic drugs for CRBD should be investigated to improve patient comfort in all surgery patients with a urinary catheter.

A prospective, randomized, placebo-controlled study will be conducted to investigate whether hyoscine-n-butylbromide has preventive effects on early postoperative CRBD in patients with urinary catheters who will undergo elective cesarean sections.

Enrollment

92 patients

Sex

Female

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Elective primary or repeat cesarean section at or more than 38 weeks of gestation scheduled to insert a Foley catheter in the operation site.

Exclusion criteria

  • • Urinary infection (assessed clinically and by urinalysis of midstream sample of urine (MSSU) with chemical indicator strips or dipsticks).

    • Contraindications for general anesthesia.
    • Maternal bladder, urethral and renal disorders causing irritating voiding problems such as dysuria, urge and stress incontinence.
    • Obstructive voiding symptoms like incomplete emptying, straining and voiding difficulty before surgery.
    • Overactive bladder (frequency: more than three times during the night or more than eight times in 24 h).
    • Morbid obesity.
    • Disturbances of the central nervous system (epilepsy, patients receiving MAO inhibitor).
    • Hypertensive disorders and/ or systemic disease requiring particular patient care (for example, cardiac disease, nephritic disorders).
    • Chronic analgesic abuse.
    • Hepatic or psychiatric disease will be excluded from the study.
    • A history of hypersensitivity or contraindication to hyoscine-n-butylbromide.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

92 participants in 2 patient groups, including a placebo group

hyoscine-n-butylbromide group
Experimental group
Description:
one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
Treatment:
Drug: hyoscine-n-butylbromide
control group
Placebo Comparator group
Description:
the same volume (1 ml) of normal saline intravenously immediately before the end of the cesarean section.
Treatment:
Drug: control group

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems